INTELLECTUAL PROPERTY
Protalex is building a strong proprietary position with multiple patents pending; chief among them is the “Protein A Compositions and Methods of Use” patent which was filed with the U.S. Patent and Trademark Office in April 2002. This broad use patent protects the company’s lead compound PRTX-100 for treatment of a variety of autoimmune diseases in addition to idiopathic thrombocytopenic purpura and rheumatoid arthritis, providing a significant barrier to entry for others. The Company has also filed for foreign protection relating to this patent in Canada, Japan and the European Union. Additionally, patent applications relating to the manufacturing process of PRTX-100 and new compounds are currently in process.